These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9246681)

  • 1. Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells.
    Li B; Hughes JA; Phillips MI
    Neurochem Int; 1997 Sep; 31(3):393-403. PubMed ID: 9246681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course of inhibition of hypertension by antisense oligonucleotides targeted to AT1 angiotensin receptor mRNA in spontaneously hypertensive rats.
    Gyurko R; Tran D; Phillips MI
    Am J Hypertens; 1997 May; 10(5 Pt 2):56S-62S. PubMed ID: 9160782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood.
    Peng JF; Kimura B; Fregly MJ; Phillips MI
    Hypertension; 1998 Jun; 31(6):1317-23. PubMed ID: 9622148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin.
    Gyurko R; Wielbo D; Phillips MI
    Regul Pept; 1993 Dec; 49(2):167-74. PubMed ID: 8134617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical role of AT1 receptor expression after ischemia/reperfusion in isolated rat hearts: beneficial effect of antisense oligodeoxynucleotides directed at AT1 receptor mRNA.
    Yang BC; Phillips MI; Zhang YC; Kimura B; Shen LP; Mehta P; Mehta JL
    Circ Res; 1998 Sep; 83(5):552-9. PubMed ID: 9734478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo effects of partial phosphorothioated AT1 receptor antisense oligonucleotides in spontaneously hypertensive and normotensive rats.
    Piegari E; Galderisi U; Berrino L; Di Bernardo G; Cipollaro M; Esposito F; Rossi F; Cascino A
    Life Sci; 2000 Apr; 66(21):2091-9. PubMed ID: 10823348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide to AT1 receptor mRNA inhibits central angiotensin induced thirst and vasopressin.
    Meng H; Wielbo D; Gyurko R; Phillips MI
    Regul Pept; 1994 Dec; 54(2-3):543-51. PubMed ID: 7716285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
    Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
    J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
    Hu Q; Bally MB; Madden TD
    Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
    Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
    Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of multidrug resistance in human leukemia cells with mdr1-targeted antisense oligonucleotides using variable treatment schedules.
    Dassow H; Lassner D; Remke H; Preiss R
    Int J Clin Pharmacol Ther; 2000 Apr; 38(4):209-16. PubMed ID: 10783831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries.
    Ho SP; Bao Y; Lesher T; Malhotra R; Ma LY; Fluharty SJ; Sakai RR
    Nat Biotechnol; 1998 Jan; 16(1):59-63. PubMed ID: 9447595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.
    Morishita R; Gibbons GH; Ellison KE; Nakajima M; von der Leyen H; Zhang L; Kaneda Y; Ogihara T; Dzau VJ
    J Clin Invest; 1994 Apr; 93(4):1458-64. PubMed ID: 8163650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.
    Yoo BH; Bochkareva E; Bochkarev A; Mou TC; Gray DM
    Nucleic Acids Res; 2004; 32(6):2008-16. PubMed ID: 15064360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects.
    Hu Q; Shew CR; Bally MB; Madden TD
    Biochim Biophys Acta; 2001 Sep; 1514(1):1-13. PubMed ID: 11513800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes.
    Phillips MI; Wielbo D; Gyurko R
    Kidney Int; 1994 Dec; 46(6):1554-6. PubMed ID: 7700004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
    Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
    J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle-dependent distribution and specific inhibitory effect of vectorized antisense oligonucleotides in cell culture.
    Hélin V; Gottikh M; Mishal Z; Subra F; Malvy C; Lavignon M
    Biochem Pharmacol; 1999 Jul; 58(1):95-107. PubMed ID: 10403523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection reagent, FuGENE6, in HeLa cells.
    Tamura Y; Tao M; Miyano-Kurosaki N; Takai K; Takaku H
    Antisense Nucleic Acid Drug Dev; 2000 Apr; 10(2):87-96. PubMed ID: 10805159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.